|
1
|
Martling AL, Holm T, Rutqvist LE, Moran
BJ, Heald RJ and Cedemark B: Effect of a surgical training
programme on outcome of rectal cancer in the county of Stockholm.
Stockholm Colorectal Cancer Study Group Basingstoke Bowel Cancer
Research Project. Lancet. 356:93–96. 2000. View Article : Google Scholar
|
|
2
|
Heald RJ and Ryall RD: Recurrence and
survival after total mesorectal excision for rectal cancer. Lancet.
1:1479–1482. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Enker WE, Thaler HT, Cranor ML and Polyak
T: Total mesorectal excision in the operative treatment of
carcinoma of the rectum. J Am Coll Surg. 181:335–346.
1995.PubMed/NCBI
|
|
4
|
Peeters KC, Marijnen CA, Nagtegaal ID, et
al: The TME trial after a median follow-up of 6 years: increased
local control but no survival benefit in irradiated patients with
resectable rectal carcinoma. Ann Surg. 246:693–701. 2007.
|
|
5
|
Pacelli F, Tortorelli AP, Rosa F, et al:
Locally recurrent rectal cancer: prognostic factors and long-term
outcomes of multimodal therapy. Ann Surg Oncol. 17:152–162. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Den Dulk M, Marijnen CA, Putter H, et al:
Risk factors for adverse outcome in patients with rectal cancer
treated with an abdominoperineal resection in the total mesorectal
excision trial. Ann Surg. 246:83–90. 2007.PubMed/NCBI
|
|
7
|
No authors listed. Improved survival with
preoperative radiotherapy in resectable rectal cancer. Swedish
Rectal Cancer Trial. N Engl J Med. 336:980–987. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim YK, Law WL, Liu R, Poon JT, Fan JF and
Lo OS: Impact of neoadjuvant treatment on total mesorectal excision
for ultra-low rectal cancers. World J Surg Oncol. 8:232010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kusters M, Marijnen CA, van de Velde CJ,
et al: Patterns of local recurrence in rectal cancer a study of the
Dutch TME trial. Eur J Surg Oncol. 36:470–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rullier E, Goffre B, Bonnel C, Zerbib F,
Caudry M and Saric J: Preoperative radiochemotherapy and
sphincter-saving resection for T3 carcinomas of the lower third of
the rectum. Ann Surg. 234:633–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim DW, Lim SB, Kim DY, et al:
Pre-operative chemo-radiotherapy improves the sphincter
preservation rate in patients with rectal cancer located within 3
cm of the anal verge. Eur J Surg Oncol. 32:162–167. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bujko K, Nowacki MP, Nasierowska-Guttmejer
A, Michalski W, Bebenek M, Pudełko M, Kryj M, Oledzki J, Szmeja J,
Słuszniak J, et al: Sphincter preservation following preoperative
radiotherapy for rectal cancer: report of a randomised trial
comparing short-term radiotherapy vs. conventionally fractionated
radiochemotherapy. Radiother Oncol. 72:15–24. 2004. View Article : Google Scholar
|
|
14
|
Xu AG, Yu ZJ, Jiang B, et al: Colorectal
cancer in Guangdong Province of China: a demographic and anatomic
survey. World J Gastroenterol. 16:960–965. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smalley SR, Benedetti JK, Williamson SK,
Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA,
Kugler JW, et al: Phase III trial of fluorouracil-based
chemotherapy regimens plus radiotherapy in postoperative adjuvant
rectal cancer: GI INT 0144. J Clin Oncol. 24:3542–3547. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kornmann M, Staib L, Wiegel T, et al:
Adjuvant chemoradiotherapy of advanced resectable rectal cancer:
results of a randomised trial comparing modulation of
5-fluorouracil with folinic acid or with interferon-α. Br J Cancer.
103:1163–1172. 2010.
|
|
17
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, et al: Preoperative radiotherapy with or without
concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006.PubMed/NCBI
|
|
18
|
Huh JW, Kim CH, Kim HR and Kim YJ:
Oncologic outcomes of pathologic stage I lower rectal cancer with
or without preoperative chemoradiotherapy: are they comparable?
Surgery. 150:980–984. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sauer R, Fietkau R, Wittekind C, Rödel C,
Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH,
Becker H, et al: Adjuvant vs. neoadjuvant radiochemotherapy for
locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
Colorectal Dis. 5:406–415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N
Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roh MS, Colangelo LH, O’Connell MJ, et al:
Preoperative multimodality therapy improves disease-free survival
in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol.
27:5124–5130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weiser MR, Quah HM, Shia J, et al:
Sphincter preservation in low rectal cancer is facilitated by
preoperative chemoradiation and intersphincteric dissection. Ann
Surg. 249:236–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim YW, Kim NK, Min BS, et al: Factors
associated with anastomotic recurrence after total mesorectal
excision in rectal cancer patients. J Surg Oncol. 99:58–64. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Das P, Skibber JM, Rodriguez-Bigas MA,
Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME,
et al: Clinical and pathologic predictors of locoregional
recurrence, distant metastasis, and overall survival in patients
treated with chemoradiation and mesorectal excision for rectal
cancer. Am J Clin Oncol. 29:219–224. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuo LJ, Liu MC, Jian JJ, et al: Is final
TNM staging a predictor for survival in locally advanced rectal
cancer after preoperative chemoradiation therapy? Ann Surg Oncol.
14:2766–2772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herzog T, Belyaev O, Chromik AM, et al:
TME quality in rectal cancer surgery. Eur J Med Res. 15:292–296.
2010.PubMed/NCBI
|
|
27
|
Ferenschild FT, Dawson I, de Wilt JH, de
Graaf EJ, Groenendijk RP and Tetteroo GW: Total mesorectal excision
for rectal cancer in an unselected population: quality assessment
in a low volume center. Int J Colorectal Dis. 24:923–929.
2009.PubMed/NCBI
|
|
28
|
Theodoropoulos G, Wise WE, Padmanabhan A,
et al: T-level downstaging and complete pathologic response after
preoperative chemoradiation for advanced rectal cancer result in
decreased recurrence and improved disease-free survival. Dis Colon
Rectum. 45:895–903. 2002. View Article : Google Scholar
|
|
29
|
Elwanis MA, Maximous DW, Elsayed MI and
Mikhail NN: Surgical treatment for locally advanced lower third
rectal cancer after neoadjuvent chemoradiation with capecitabine:
prospective phase II trial. World J Surg Oncol. 7:522009.
View Article : Google Scholar
|
|
30
|
Canda AE, Terzi C, Gorken IB, Oztop I,
Sokmen S and Fuzun M: Effects of preoperative chemoradiotherapy on
anal sphincter functions and quality of life in rectal cancer
patients. Int J Colorectal Dis. 25:197–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ammann K, Kirchmayr W, Klaus A, et al:
Impact of neoadjuvant chemoradiation on anal sphincter function in
patients with carcinoma of the midrectum and low rectum. Arch Surg.
138:257–261. 2003. View Article : Google Scholar : PubMed/NCBI
|
